Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003294 | 0.90 | GLP1R (0.58) | GLP1RNOD1FOLH1 | |
| SCHEMBL21725212 | 0.89 | GLP1R (0.55) | GLP1RNOD1FOLH1 | |
| SCHEMBL14239442 | 0.88 | GLP1R (0.59) | GLP1RNOD1ALBFOLH1 | |
| SCHEMBL19135682 | 0.88 | GLP1R (0.51) | GLP1RNOD1 | |
| SCHEMBL24787610 | 0.88 | NOD1 (0.58) | NOD1ALBFOLH1 | |
| SCHEMBL13880485 | 0.87 | GLP1R (0.58) | GLP1RALBFOLH1 | |
| SCHEMBL26076118 | 0.87 | GLP1R (0.77) | GLP1RNOD1 | |
| SCHEMBL21110472 | 0.87 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249859 | 0.87 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034796 | 0.87 | GLP1R (0.68) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535650-B1 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-10918691-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200155639-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918691-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885ALB 2293/4885 |
| US-20200155639-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885ALB 2293/4885 |
| US-11535650-B1 | Modulation of complement activity | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885ALB 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.